Author:
Seidi Khaled,Jahanban-Esfahlan Rana,Monhemi Hassan,Zare Peyman,Minofar Babak,Daei Farshchi Adli Amir,Farajzadeh Davoud,Behzadi Ramezan,Mesgari Abbasi Mehran,Neubauer Heidi A.,Moriggl Richard,Zarghami Nosratollah,Javaheri Tahereh
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Molecular Biology
Reference49 articles.
1. Jahanban-Esfahlan R, Seidi K, Zarghami N. Tumor vascular infarction: prospects and challenges. Int J Hematol. 2017;105:244–56.
2. Bieker R, Kessler T, Schwoppe C, Padro T, Persigehl T, Bremer C, et al. Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in-man experience. Blood. 2009;113:5019–27.
3. Brand C, Schliemann C, Ring J, Kessler T, Bäumer S, Angenendt L, et al. NG2 proteoglycan as a pericyte target for anticancer therapy by tumor vessel infarction with retargeted tissue factor. Oncotarget. 2016;7:6774–89.
4. Hu P, Yan J, Sharifi J, Bai T, Khawli LA, Epstein AL. Comparison of three different targeted tissue factor fusion proteins for inducing tumor vessel thrombosis. Cancer Res. 2003;63:5046–53.
5. Huang FY, Li YN, Wang H, Huang YH, Lin YY, Tan GH. A fusion protein containing murine vascular endothelial growth factor and tissue factor induces thrombogenesis and suppression of tumor growth in a colon carcinoma model. J Zhejiang Univ Sci B. 2008;9:602–9.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献